What is the 13F Pro Quality Score for ZNTL?

13F Pro ranks Zentalis Pharmaceuticals, Inc. (ZNTL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ZNTL's current score at https://13fpro.ai/research/ZNTL (free sign-up required for the full ranking).

Where does 13F Pro source ZNTL data?

All Zentalis Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Zentalis Pharmaceuticals, Inc. files with the SEC under CIK 1725160. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ZNTL in?

Zentalis Pharmaceuticals, Inc. (ZNTL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ZNTL research updated on 13F Pro?

ZNTL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Zentalis Pharmaceuticals, Inc.(ZNTL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1725160 ZNTL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ZNTL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Zentalis Pharmaceuticals, Inc. (ZNTL), a Healthcare sector company. ZNTL is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Zentalis Pharmaceuticals, Inc. reports net income of $-35.4M, free cash flow of $-33.0M. Top institutional holders of ZNTL by reported 13-F value include 5AM Venture Management,, Squadron Capital Management, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. ZNTL trades on the Nasdaq exchange and files with the SEC under CIK 1725160. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZNTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zentalis Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-35.4M

Free Cash Flow

Q1 2026

$-33.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY18 —FY23 $0.00FY24 $67.4MFY25 $0.00

Net Income

+17.4% YoY

$-137.1MFY 2025

FY18 —FY23 $-292.3MFY24 $-165.8MFY25 $-137.1M

Operating Income

+20.1% YoY

$-152.8MFY 2025

FY18 —FY23 $-299.5MFY24 $-191.2MFY25 $-152.8M

EPS (Diluted)

+18.0% YoY

$-1.91FY 2025

FY18 —FY23 $-4.47FY24 $-2.33FY25 $-1.91

Total Assets

-32.9% YoY

$289.0MFY 2025

FY18 —FY23 $551.7MFY24 $430.3MFY25 $289.0M

Op. Cash Flow

+26.7% YoY

$-125.2MFY 2025

FY18 —FY23 $-207.8MFY24 $-170.9MFY25 $-125.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2018
Revenue	$0.00 -100.0%	$67.4M	$0.00	—
Net Income	$-137.1M +17.4%	$-165.8M +43.3%	$-292.3M	—
Operating Income	$-152.8M +20.1%	$-191.2M +36.2%	$-299.5M	—
EPS (Diluted)	$-1.91 +18.0%	$-2.33 +47.9%	$-4.47	—
Total Assets	$289.0M -32.9%	$430.3M -22.0%	$551.7M	—
Operating Cash Flow	$-125.2M +26.7%	$-170.9M +17.8%	$-207.8M	—

AI Insight: ZNTL Financial Trends

Zentalis continues burning cash with zero revenue in Q1 2026, while equity has eroded 52% from $383M to $183M over eight quarters.

• Revenue has been zero every quarter except a one-time $27M in Q4 2024, with nothing reported in Q1 2026.

• Equity has declined steadily from $383M in Q2 2024 to $183M in Q1 2026, a $200M erosion over eight quarters.

• Operating losses improved modestly from -$65M in Q2 2024 to -$34M in Q3 2025, but ticked back to -$38M in Q1 2026.

• Operating cash burn narrowed from -$44M in Q3 2024 to -$27M in Q3 2025, but remains -$33M in Q1 2026.

⚠ Equity at $183M and quarterly cash burn near -$33M implies roughly five to six quarters of runway without new financing.

⚠ No debt reported is a modest buffer, but absence of revenue means the company is entirely dependent on capital markets.

⚠ The one-time $27M revenue in Q4 2024 did not recur — watch for any milestone, partnership, or licensing event that restores revenue.

AI Insight: ZNTL Ratio Trends

ROIC has deteriorated sharply to -82.9% in Q1 2026, reversing a mid-2025 improvement and signaling deepening capital destruction.

• ROIC improved from -68.1% in Q2 2024 to -52.5% in Q2 2025, suggesting brief capital efficiency gains mid-cycle.

• ROIC reversed sharply, worsening from -52.5% in Q2 2025 to -82.9% in Q1 2026 — a 30pp deterioration in three quarters.

• ROA followed the same arc, bottoming at -71.8% in Q2 2024, recovering to -30.6% in Q2 2025, then sliding to -55.9% in Q1 2026.

⚠ ROIC at -82.9% in Q1 2026 is the worst reading in the dataset — capital burn is accelerating, not stabilizing.

⚠ OpMargin and NPM data are absent for most periods; limited visibility into operating cost trajectory is a key analytical gap.

Get alerted when ZNTL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Zentalis Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ZNTL

5AM Venture Management, LLC
$9.2M3,947,913 sh
Squadron Capital Management LLC
$8.5M3,631,000 sh
TWO SIGMA INVESTMENTS, LP
$6.9M2,956,526 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.4M2,310,707 sh
RENAISSANCE TECHNOLOGIES LLC
$4.5M1,938,145 sh
CITADEL ADVISORS LLC
$4.1M1,732,083 sh
D. E. Shaw & Co., Inc.
$3.5M1,484,098 sh
Opaleye Management Inc.
$3.3M1,412,656 sh
Decheng Capital LLC
$3.1M1,323,327 sh
MILLENNIUM MANAGEMENT LLC
$3.0M1,289,822 sh

Fund	Value	Shares
5AM Venture Management, LLC	$9.2M	3,947,913
Squadron Capital Management LLC	$8.5M	3,631,000
TWO SIGMA INVESTMENTS, LP	$6.9M	2,956,526
VANGUARD CAPITAL MANAGEMENT LLC	$5.4M	2,310,707
RENAISSANCE TECHNOLOGIES LLC	$4.5M	1,938,145
CITADEL ADVISORS LLC	$4.1M	1,732,083
D. E. Shaw & Co., Inc.	$3.5M	1,484,098
Opaleye Management Inc.	$3.3M	1,412,656
Decheng Capital LLC	$3.1M	1,323,327
MILLENNIUM MANAGEMENT LLC	$3.0M	1,289,822

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ZNTL on your watchlist

Track score changes the day Zentalis Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ZNTL a good stock to buy?

13F Pro's AI-powered analysis of Zentalis Pharmaceuticals, Inc. (ZNTL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZNTL are available on the ZNTL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ZNTL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZNTL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zentalis Pharmaceuticals, Inc.'s investment landscape.